Autologous Fat: Definition, Composition, Biology, Uses and Safety

What is autologous fat?

Autologous fat is adipose tissue that comes from the same person who receives it. The US National Cancer Institute defines 'autologous' as taken from an individual's own tissues, cells or DNA [1]. The opposite terms are 'allogeneic', meaning from another person, and 'synthetic', meaning a manufactured material such as an injectable filler or an implant. In clinical use, autologous fat is usually removed by liposuction, prepared to remove blood, oil and fluid, and then re-injected into a recipient site. This procedure is called fat grafting, fat transfer or lipofilling.

The term covers the tissue itself, not one particular operation. The same harvested fat can be injected as tissue for volume, or processed further in a laboratory or at the bedside to concentrate its cells. That second route produces the stromal vascular fraction (SVF), which is covered on separate pages.

What autologous fat contains

Adipose tissue is more than a mass of fat cells. Liposuction samples contain a mixed population of cells: mature adipocytes, endothelial cells (which line blood vessels), pericytes, preadipocytes and fibroblasts. When fat is processed into SVF, adipose-derived stem cells make up only a small part of that mixture [4]. Clinical reviews describe fat tissue as adipocytes plus the stromal vascular fraction and adipose-derived stem cells [5].

Advantages of using a patient's own fat

Clinical reviews give several reasons for using autologous fat. Because the tissue is autologous, it carries no rejection risk and no allergy or viral-transmission concerns. The material is plentiful, easy to reach and inexpensive, and its stem cells may help with tissue repair [5]. Harvesting fat also reduces fat at the donor site, which is why fat transfer is often combined with liposuction.

These advantages concern immunology and availability. They do not mean the graft will survive. Autologous fat still carries the risks of surgery at two sites: the donor site and the recipient site.

Why your own fat does not always survive after transfer

Injected fat is a non-vascularized graft. For the first days it has no blood vessels of its own and has to rely on nearby tissue for oxygen and nutrients. One review reports that revascularization of transplanted fat begins only after about 48 hours. That delay can seriously harm fat-cell survival, and the cells then degenerate [4].

The three-zone model

An experimental study by Eto, Yoshimura and colleagues, published in Plastic and Reconstructive Surgery in 2012, followed grafted fat in mice and in human tissue samples. It described three zones running from the edge to the centre of a graft [3]:

• Surviving zone: near the edge of the graft, where adipocytes survive. On day 1, only adipocytes within about 300 μm of the tissue edge had survived [3].
• Regenerating zone: adipocytes die, but stromal cells survive and replace them with new adipocytes [3].
• Necrotic zone: at the centre, both adipocytes and stromal cells die [3].

In the same study, cell proliferation increased by day 3, and the area of viable adipocytes had grown by day 7 [3]. The model helps explain why practitioners inject fat in small amounts. Coleman's technique, for example, places no more than 0.1 mL per pass so that the fat stays close to a blood supply [2].

How much fat is retained

Published estimates of how much fat is lost after transfer vary widely. One review gives a resorption rate of 25% to 80%, depending on technique and conditions at the recipient site [4]. Another clinical review reports overall graft survival of 50–90% even among experienced surgeons [5]. In the 1950s, Peer found that about 50% of fat cells ruptured and died after transplantation, and that fibrous tissue replaced part of the graft [2]. The differences in these figures reflect different measurement methods, recipient sites, follow-up periods and techniques, so a single 'survival rate' should be read with care.

How autologous fat is harvested and prepared

Preparation affects how many cells stay alive. One review suggests harvesting with a 2 mm blunt-tipped cannula and 10 mL syringes rather than 60 mL syringes, centrifuging at 3,000 rpm for 3 minutes to clear most blood remnants, and injecting about 0.1 mL per pass [5]. Coleman's method uses 3 mm blunt cannulas, centrifugation for purification and small-aliquot placement [2]. Techniques vary between surgeons, and there is no single standard protocol.

Does the donor site matter?

The lower abdomen and inner thigh have been reported to contain more adipose-derived stem cells than other donor sites [5]. For graft survival, a 2026 systematic review in JPRAS Open looked at 7 studies with 291 patients who had fat transferred to the breast. Pooled mean survival was 56.04% for abdominal fat at 12 months and 34.13% for thigh fat at 6 months [7]. Only one study compared the two donor sites directly, however. The authors concluded that no donor site can be recommended based on fat graft survival alone [7].

Clinical uses of autologous fat

• Soft-tissue volume restoration: filling hollow areas of the face and body, and correcting contour defects.
• Breast reconstruction and augmentation: a lipoma was used to fill a breast lumpectomy defect as early as 1895 [2].
• Scar and burn treatment, and neuropathic pain: current uses include remodelling scars, treating burns and relieving neuropathic pain [2].
• Source material for cell-based preparations: SVF and cell-assisted lipotransfer. In one randomized trial cited in a review, stem-cell-enriched grafts kept 81% of their volume compared with 16% in the non-enriched group [4]. That is a single trial, not a general benchmark.

Safety profile

A systematic review and meta-analysis in Cureus, published in November 2025, pooled 42 studies with 6,268 patients from 2008 to 2024. It found an overall complication rate of 4.2% (95% CI 2.7–6.0) [6].

By recipient site, the same review reported complication rates of 7.5% for the breast, 4.0% for the face and 4.8% for the buttocks [6]. The authors noted that studies differed widely in technique, processing and sites, which limits comparisons [6]. Clinical reviews describe fat resorption as the most common problem and blood-vessel blockage or embolism as the most serious [5].

Fat embolism in gluteal fat grafting

In 2017, a task force of the Aesthetic Surgery Education and Research Foundation surveyed 4,843 plastic surgeons. The 692 who responded reported 198,857 gluteal fat grafting cases, 32 deaths from pulmonary fat embolism and 103 non-fatal pulmonary fat emboli over their careers [8]. The task force concluded that gluteal fat grafting appears to have significantly higher mortality than any other aesthetic surgical procedure. It recommended avoiding injection into deep muscle, cannulas smaller than 4 mm and downward-angled cannulas [8]. This shows that an autologous material can still be dangerous depending on where and how it is injected.

Regulatory status

In the United States, the FDA regulates human cells and tissues under 21 CFR Part 1271. Its Center for Biologics Evaluation and Research issued guidance in November 2017 on the 'same surgical procedure' exception in 21 CFR 1271.15(b) [9]. That exception can apply to autologous tissue that is removed and put back during the same operation. A review of minimal-manipulation strategies notes that using collagenase to digest fat and isolate SVF is considered more than minimal manipulation, because it substantially changes the tissue's original characteristics. Such processing is mostly limited to controlled clinical trials [10]. Mechanical steps such as centrifugation are grouped with minimal manipulation [10]. Rules differ between countries.

A brief history

Limitations of the evidence

Much of the clinical evidence on autologous fat comes from retrospective cohorts. Of the 42 studies in the 2025 meta-analysis, 33 were retrospective and only 1 was a randomized controlled trial [6]. Harvesting, processing and measurement methods are not standardized, so reported retention and complication rates are hard to compare across studies. Anyone considering a procedure that uses autologous fat should discuss the expected volume loss, the possible need for repeat sessions and the risks at each site with a qualified clinician.